Home/Pipeline/Immune-Oncology Programs

Immune-Oncology Programs

Solid Tumors

ResearchActive

Key Facts

Indication

Solid Tumors

Phase

Research

Status

Active

Company

Velvio

About Velvio

Velvio is a preclinical-stage biotech targeting a central biological pathway, TGF-β signaling, with a proprietary LNA-gapmer antisense oligonucleotide platform. Its lead candidate, NVP-13, is designed to downregulate TGFBR2 synthesis to revert inflammation, fibrosis, and restore tissue repair, with first-in-human studies imminent in ALS. The company is pursuing high-unmet-need indications in neurodegeneration, pulmonary fibrosis, and oncology, positioning its platform technology for broad therapeutic application. Led by a small team of experienced founders, Velvio is advancing towards clinical proof-of-concept.

View full company profile

Therapeutic Areas

Neurodegeneration Pulmonary Fibrosis Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed